miR-196a Upregulation Contributes to Gefitinib Resistance through Inhibiting GLTP Expression

Tyrosine kinase inhibitor (TKI) therapy has greatly improved lung cancer survival in patients with epidermal growth factor receptor (EGFR) mutations. However, the development of TKI-acquired resistance is the major problem to be overcome. In this study, we found that miR-196a expression was greatly...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Bing-Jie, Li, Fang-Fang, Xie, Yun-Xia, Fan, Chong-Yuan, Liu, Wen-Jing, Qiu, Jian-Ge, Jiang, Bing-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836598/
https://www.ncbi.nlm.nih.gov/pubmed/35163707
http://dx.doi.org/10.3390/ijms23031785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836598/
https://www.ncbi.nlm.nih.gov/pubmed/35163707
http://dx.doi.org/10.3390/ijms23031785

Ejemplares similares